New hope for prostate cancer: Lower-Dose chemo combo shows promise
NCT ID NCT07503379
First seen Apr 02, 2026 · Last updated May 14, 2026 · Updated 7 times
Summary
This study is for men with metastatic hormone-sensitive prostate cancer (mHSPC) that has spread. It tests a combination of darolutamide, hormone therapy (ADT), and a lower dose of the chemotherapy drug docetaxel. The goal is to see if this approach can make PSA levels undetectable (below 0.2 ng/ml) after 24 weeks while reducing side effects. About 109 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MHSPC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Affiliated Cancer Hospital of Guangzhou Medical University
Guangzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Meizhou People's Hospital
Meizhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.